Ara h 1 CD4+ T cell epitope-based peptides: Candidates for a peanut allergy therapeutic

Clinical and Experimental Allergy

Volumn 43, Issue 6, 2013, Pages 684-697

  Prickett, S R ^a,b   Voskamp, A L ^a,b   Phan, T ^a,b   Dacumos Hill, A ^a,b   Mannering, S I ^c   Rolland, J M ^a,b   O'Hehir, R E ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Ara h 1; CD4+ T cell; Immunotherapy; Peanut allergy; Peptide; T cell epitope

Indexed keywords

ARA H 1 PEPTIDE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; EPITOPE; PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BASOPHIL; CD4+ T LYMPHOCYTE; CELL ACTIVATION; EPITOPE MAPPING; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PEANUT; PEANUT ALLERGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENS, PLANT; BASOPHILS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; GLYCOPROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN E; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEANUT HYPERSENSITIVITY; PEPTIDES; PLANT PROTEINS;

EID: 84878356872     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12113     Document Type: Article

References (77)

1. Bock SA, Munoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016-8.
2. Burks AW. Peanut allergy. Lancet 2008; 371:1538-46.
3. Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 2010; 125:1322-6.
4. Husain Z, Schwartz RA. Peanut allergy: an increasingly common life-threatening disorder. J Am Acad Dermatol 2012; 66:136-43.
5. Kemp AS, Hu W. Food allergy and anaphylaxis - dealing with uncertainty. Med J Aust 2008; 188:503-4.
6. Busse PJ, Nowak-Wegrzyn AH, Noone SA, Sampson HA, Sicherer SH. Recurrent peanut allergy. N Engl J Med 2002; 347:1535-6.
7. Yun J, Katelaris CH. Food allergy in adolescents and adults. Intern Med J 2009; 39:475-8.
8. Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. Pediatr Allergy Immunol 2003; 14:378-82.
9. Sampson MA, Munoz-Furlong A, Sicherer SH. Risk-taking and coping strategies of adolescents and young adults with food allergy. J Allergy Clin Immunol 2006; 117:1440-5.
10. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. [see comment]. J Allergy Clin Immunol 1992; 90:256-62.
11. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4:285-90.
12. Varshney P, Steele PH, Vickery BP et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol 2009; 124:1351-2.
13. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997; 99(6 Pt 1):744-51.
14. Jones SM, Pons L, Roberts JL et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 24:292-300.
15. Varshney P, Jones SM, Scurlock AM et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011; 127:654-60.
16. Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 2011; 41:1273-81.
17. Allen KJ, O'Hehir RE. The evolution of oral immunotherapy for the treatment of peanut allergy. Clin Exp Allergy 2011; 41:1172-4.
18. Thyagarajan A, Varshney P, Jones SM et al. Peanut oral immunotherapy is not ready for clinical use. J Allergy Clin Immunol 2010; 126:31-2.
19. Hofmann AM, Scurlock AM, Jones SM et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 2009; 124:286-91.
20. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 2010; 22:609-15.
21. Rolland JM, Gardner LM. O'Hehir R E. Functional regulatory T cells and allergen immunotherapy. Curr Opin Allergy Clin Immunol 2010; 10:559-66.
22. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127:18-27; quiz 8-9.
23. Alexander C, Ying S. A BK, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005; 35:52-8.
24. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:1269-74.
25. Campbell JD, Buckland KF, McMillan SJ et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009; 206:1535-47.
26. Kay AB, Larche M. Allergen immunotherapy with cat allergen peptides. Springer Semin Immunopathol 2004; 25:391-9.
27. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47-53.
28. Muller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101(6 Pt 1):747-54.
29. Kammerer R, Chvatchko Y, Kettner A, Dufour N, Corradin G, Spertini F. Modulation of T-cell response to phospholipase A2 and phospholipase A2-derived peptides by conventional bee venom immunotherapy. J Allergy Clin Immunol 1997; 100:96-103.
30. Yang M, Yang C, Mine Y. Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3- and transforming growth factor-beta-associated mechanisms. Clin Exp Allergy 2010; 40:668-78.
31. Yoshitomi T, Nakagami Y, Hirahara K, Taniguchi Y, Sakaguchi M, Yamashita M. Intraoral administration of a T-cell epitope peptide induces immunological tolerance in Cry j 2-sensitized mice. J Pept Sci 2007; 13:499-503.
32. Marazuela EG, Rodriguez R, Fernandez-Garcia H, Garcia MS, Villalba M, Batanero E. Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen. Mol Immunol 2008; 45:438-45.
33. Rupa P, Mine Y. Oral immunotherapy with immunodominant T-cell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy. Allergy 2012; 67:74-82.
34. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993; 178:1783-8.
35. Hall G, Houghton CG, Rahbek JU, Lamb JR, Jarman ER. Suppression of allergen reactive Th2 mediated responses and pulmonary eosinophilia by intranasal administration of an immunodominant peptide is linked to IL-10 production. Vaccine 2003; 21:549-61.
36. Allergen Nomenclature, International Union of Immunological Societies [database on the Internet]. [cited 2010]. Available from: http://www.allergen.org/Allergen.aspx.
37. de Leon MP, Rolland JM, O'Hehir RE. The peanut allergy epidemic: allergen molecular characterisation and prospects for specific therapy. Expert Rev Mol Med 2007; 9:1-18.
38. Palmer K, Burks W. Current developments in peanut allergy. Curr Opin Allergy Clin Immunol 2006; 6:202-6.
39. Blanc F, Adel-Patient K, Drumare MF, Paty E, Wal JM, Bernard H. Capacity of purified peanut allergens to induce degranulation in a functional in vitro assay: Ara h 2 and Ara h 6 are the most efficient elicitors. Clin Exp Allergy 2009; 39:1277-85.
40. Koppelman SJ, Wensing M, Ertmann M, Knulst AC, Knol EF. Relevance of Ara h1, Ara h2 and Ara h3 in peanut-allergic patients, as determined by immunoglobulin E Western blotting, basophil-histamine release and intracutaneous testing: Ara h2 is the most important peanut allergen. Clin Exp Allergy 2004; 34:583-90.
41. Palmer GW, Dibbern DA Jr, Burks AW et al. Comparative potency of Ara h 1 and Ara h 2 in immunochemical and functional assays of allergenicity. Clin Immunol 2005; 115:302-12.
42. Glaumann S, Nopp A, Johansson SG, Rudengren M, Borres MP, Nilsson C. Basophil allergen threshold sensitivity, CD-sens, IgE-sensitization and DBPCFC in peanut-sensitized children. Allergy 2012; 67:242-7.
43. Chiang WC, Pons L, Kidon MI, Liew WK, Goh A, Wesley Burks A. Serological and clinical characteristics of children with peanut sensitization in an Asian community. Pediatr Allergy Immunol. 2009;21(2 Pt 2):e429-38.
44. Asarnoj A, Moverare R, Ostblom E et al. IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds. Allergy. 2010; 65:1189-95.
45. Moverare R, Ahlstedt S, Bengtsson U et al. Evaluation of IgE antibodies to recombinant peanut allergens in patients with reported reactions to peanut. Int Arch Allergy Immunol 2011; 156:282-90.
46. Lin YT, Charles Wu CT, Cheng JH, Huang JL, Yeh KW. Patterns of sensitization to peanut allergen components in Taiwanese Preschool children. J Microbiol Immunol Infect 2012; 45:90-5.
47. Peeters KA, Koppelman SJ, van Hoffen E et al. Does skin prick test reactivity to purified allergens correlate with clinical severity of peanut allergy? Clin Exp Allergy 2007; 37:108-15.
48. Koppelman SJ, Vlooswijk RA, Knippels LM et al. Quantification of major peanut allergens Ara h 1 and Ara h 2 in the peanut varieties Runner, Spanish, Virginia, and Valencia, bred in different parts of the world. Allergy 2001; 56:132-7.
49. Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol 2011;127:608-15; e1-5.
50. DeLong JH, Simpson KH, Wambre E, James EA, Robinson D, Kwok WW. Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 2011; 127:1211-8; e3.
51. de Leon MP, Glaspole IN, Drew AC, Rolland JM, O'Hehir RE, Suphioglu C. Immunological analysis of allergenic cross-reactivity between peanut and tree nuts. Clin Exp Allergy 2003; 33:1273-80.
52. Eusebius NP, Papalia L, Suphioglu C et al. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (bermuda grass) pollen: pre- and post-allergen-specific immunotherapy. Int Arch Allergy Immunol 2002; 127:234-44.
53. Mannering SI, Dromey JA, Morris JS, Thearle DJ, Jensen KP, Harrison LC. An efficient method for cloning human autoantigen-specific T cells. J Immunol Methods 2005; 298:83-92.
54. Drew AC, Eusebius NP, Kenins L et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004; 173:5872-9.
55. Etto T, de Boer C, Prickett S et al. Unique and cross-reactive T cell epitope peptides of the major Bahia grass pollen allergen, Pas n 1. Int Arch Allergy Immunol 2012; 159:355-66.
56. Pascal M, Konstantinou GN, Masilamani M, Lieberman J, Sampson HA. In silico prediction of Ara h 2 T cell epitopes in peanut-allergic children. Clin Exp Allergy 2013; 43:116-27.
57. Cardaba B, Del Pozo V, Jurado A et al. Olive pollen allergy: searching for immunodominant T-cell epitopes on the Ole e 1 molecule. Clin Exp Allergy 1998; 28:413-22.
58. de Silva HD, Gardner LM, Drew AC, Beezhold DH, Rolland JM, O'Hehir RE. The hevein domain of the major latex-glove allergen Hev b 6.01 contains dominant T cell reactive sites. Clin Exp Allergy 2004; 34:611-8.
59. Oseroff C, Sidney J, Kotturi MF et al. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol 2010; 185:943-55.
60. Hemmer B, Kondo T, Gran B et al. Minimal peptide length requirements for CD4(+) T cell clones-implications for molecular mimicry and T cell survival. Int Immunol 2000; 12:375-83.
61. Suri A, Lovitch SB, Unanue ER. The wide diversity and complexity of peptides bound to class II MHC molecules. Curr Opin Immunol 2006; 18:70-7.
62. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001; 17:1236-7.
63. Vita R, Zarebski L, Greenbaum JA et al. The immune epitope database 2.0. Nucleic Acids Res 2010; 38(Database issue): D854-62.
64. Shreffler WG, Charlop-Powers Z, Sicherer SH. Lack of association of HLA class II alleles with peanut allergy.[see comment]. Ann Allergy Asthma Immunol 2006; 96:865-9.
65. Boumiza R, Debard AL, Monneret G. The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy 2005; 3:9.
66. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens. 2003; 61:403-7.
67. Shek LP, Cabrera-Morales EA, Soh SE et al. A population-based questionnaire survey on the prevalence of peanut, tree nut, and shellfish allergy in 2 Asian populations. J Allergy Clin Immunol 2010; 126:324-31; e7.
68. Bateman EA, Ardern-Jones MR, Ogg GS. Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes.[see comment]. Clin Exp Allergy 2008; 38:1760-8.
69. Verhoef A, Higgins JA, Thorpe CJ et al. Clonal analysis of the atopic immune response to the group 2 allergen of Dermatophagoides spp.: identification of HLA-DR and -DQ restricted T cell epitopes. Int Immunol 1993; 5:1589-97.
70. Higgins JA, Thorpe CJ, Hayball JD, O'Hehir RE, Lamb JR. Overlapping T-cell epitopes in the group I allergen of Dermatophagoides species restricted by HLA-DP and HLA-DR class II molecules. J Allergy Clin Immunol 1994; 93:891-9.
71. Ruiter B, Rozemuller EH, van Dijk AJ et al. Role of human leucocyte antigen DQ in the presentation of T cell epitopes in the major cow's milk allergen alphas1-casein. Int Arch Allergy Immunol 2007; 143:119-26.
72. van Neerven RJ, van de Pol MM, van Milligen FJ, Jansen HM, Aalberse RC, Kapsenberg ML. Characterization of cat dander-specific T lymphocytes from atopic patients. J Immunol 1994; 152:4203-10.
73. Larche M. Of cats and men: immunodominance and the role of HLA-DP/DQ. [comment]. Clin Exp Allergy 2008; 38:1709-11.
74. Rolland JM, Gardner LM, O'Hehir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 2009; 121:273-84.
75. Burks AW, Shin D, Cockrell G, Stanley JS, Helm RM, Bannon GA. Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity. Eur J Biochem 1997; 245:334-9.
76. Shreffler WG, Beyer K, Chu TH, Burks AW, Sampson HA. Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. J Allergy Clin Immunol 2004; 113:776-82.
77. van Boxtel EL, Koppelman SJ, van den Broek LA, Gruppen H. Determination of pepsin-susceptible and pepsin-resistant epitopes in native and heat-treated peanut allergen Ara h 1. J Agric Food Chem 2008; 56:2223-30.